Please use this identifier to cite or link to this item:
Title: Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery
Authors: Ng, S.B
Chua, C
Ng, M
Gan, A
Poon, P.S
Teo, M 
Fu, C
Leow, W.Q
Lim, K.H 
Chung, A 
Koo, S.-L
Choo, S.P 
Ho, D
Rozen, S 
Tan, P 
Wong, M 
Burkholder, W.F
Tan, I.B 
Keywords: circulating tumor DNA
tumor marker
colorectal tumor
multiplex polymerase chain reaction
postoperative period
recurrent disease
sensitivity and specificity
treatment outcome
Biomarkers, Tumor
Circulating Tumor DNA
Colorectal Neoplasms
DNA, Neoplasm
Multiplex Polymerase Chain Reaction
Postoperative Period
Reproducibility of Results
Sensitivity and Specificity
Treatment Outcome
Issue Date: 2017
Citation: Ng, S.B, Chua, C, Ng, M, Gan, A, Poon, P.S, Teo, M, Fu, C, Leow, W.Q, Lim, K.H, Chung, A, Koo, S.-L, Choo, S.P, Ho, D, Rozen, S, Tan, P, Wong, M, Burkholder, W.F, Tan, I.B (2017). Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Scientific Reports 7 : 40737. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Circulating tumour DNA (ctDNA) has the potential to be a specific biomarker for the monitoring of tumours in patients with colorectal cancer (CRC). Here, our aim was to develop a personalised surveillance strategy to monitor the clinical course of CRC after surgery. We developed patient-specific ctDNA assays based on multiplexed detection of somatic mutations identified from patient primary tumours, and applied them to detect ctDNA in 44 CRC patients, analysing a total of 260 plasma samples. We found that ctDNA detection correlated with clinical events-it is detectable in pre-operative but not post-operative plasma, and also in patients with recurrent CRC. We also detected ctDNA in 11 out of 15 cases at or before clinical or radiological recurrence of CRC, indicating the potential of our assay for early detection of metastasis. We further present data from a patient with multiple primary cancers to demonstrate the specificity of our assays to distinguish between CRC recurrence and a second primary cancer. Our approach can complement current methods for surveillance of CRC by adding an individualised biological component, allowing us not only to point to the presence of residual or recurrent disease, but also attribute it to the original cancer. © The Author(s) 2017.
Source Title: Scientific Reports
ISSN: 20452322
DOI: 10.1038/srep40737
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_srep40737.pdf2.7 MBAdobe PDF



Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons